Menu
A clinical phase biotechnology company dedicated to the development of highly innovative first-in-class antibacterials.
The team were looking to raise funding in order to continue the business’ progression towards commercialisation.
The Ruffena team succesfully raised the required funding at an angel level.
They went on to IPO in 2017, and in doing so created liquidation opportunities for the original investors which we introduced.
A clinical phase biotechnology company dedicated to the development of highly innovative first-in-class antibacterials.
The team were looking to raise funding in order to continue the business’ progression towards commercialisation.
The Ruffena team succesfully raised the required funding at an angel level.
They went on to IPO in 2017, and in doing so created liquidation opportunities for the original investors which we introduced.